Eli Lilly and Co. has reached an agreement with pharmaceutical Cipla to market tirzepatide, the active ingredient in Lilly’s ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...

The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...

Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India Tirzepatide is used to manage type 2 ...

On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...